Hutchison China MediTech

WCLC 2019: detailed FALUCA data disclosed

Update | 11 September 2019

Share this note

Top-line data from the pivotal China Phase III FALUCA fruquintinib monotherapy trial in 3L NSCLC (third-line non-small cell lung cancer), released November 2018, indicated the study missed its overall survival (OS) endpoint but met all secondary endpoints. Full data presented at the 2019 World Congress on Lung Cancer revealed median OS of 8.94 months for fruquintinib vs 10.38 months for placebo (p=0.0841). A post hoc sensitivity analysis suggested use of subsequent anti-tumour therapies following disease progression was likely to have contributed to this result. FALUCA data coupled to the rapidly evolving treatment landscape in NSCLC supports Chi-Med’s decision to focus on development of fruquintinib in combination with PD-(L)1 checkpoint inhibitors; China Phase I combination studies have begun. However, the major near-term catalyst for fruquintinib remains commercial: potential NRDL inclusion in Q419 would provide strong impetus to China revenues.

Year-end: December 31201720182019E2020E
Sales (US$m)241.2214.1183.1206.9
Adj. PBT (US$m)(53.5)(86.7)(172.1)(191.1)
Net Income (US$m)(23.0)(71.3)(135.9)(153.9)
Earnings per ADS (US$)(0.22)(0.57)(1.05)(1.18)
Cash (US$m)358.3301.0179.3271.0*
Adj. EBITDA (US$m)(17.2)(69.7)(128.8)(146.9)
Source: Trinity Delta Note: Adjusted PBT excludes exceptionals, Cash includes short-term investments, Adjusted EBITDA includes equity in earnings of equity investees. *2020E cash figure includes assumed raise of $250m.
  • Primary endpoint missed but no other surprises Full FALUCA data showed median OS for fruqunitinib monotherapy was 8.94 months vs 10.38 months for placebo (hazard ratio 1.02, p=0.841). However, all secondary endpoints were met (p<0.001), including progression free survival (PFS: 3.68 months vs 0.99 months), objective response rate (ORR: 13.8% vs 0.6%), disease control rate (DCR: 66.7% vs 24.9%), and duration of response. Fruquintinib’s safety profile was consistent with Phase II.
  • Post-hoc analysis indicates role of newer therapies Since FALUCA initiation in December 2015, several new drugs have been approved in China for use in NSCLC (ie osimertinib, anlotinib); their availability may have influenced the study result. For context, median OS was 6.3 months for placebo vs 9.6 months for anlotinib in the Phase III ALTER 0303 study in a similar NSCLC patient population. Subsequent therapies provided OS benefit to patients in both FALUCA arms but were received by a higher percentage of placebo patients. Post hoc sensitivity analysis showed that fruquintinib prolonged median OS vs placebo (7.00 months vs 5.06 months, HR 0.64, p=0.010) in patients who did not receive subsequent therapy.
  • China reimbursement to catalyse sales Potential NRDL (National Reimbursement Drug List) inclusion in Q419 would significantly boost Elunate (fruquintinib) market penetration and future revenues. Over H218/H119, the drug generated $8.3m in royalty/manufacturing revenue for Chi-Med on c$13.1m of in-market China sales.
  • Valuation remains £5.93/share and $38.55/ADS Our DCF-based SOTP model includes an rNPV of the clinical pipeline and generates a valuation of $5.14bn ($38.55/ADS) or £3.95bn (£5.93/share). We anticipate multiple clinical, regulatory, and commercial catalysts will unlock further value over the next 12 months.


11 September 2019

Price (US ADS)
(UK share)
Market Cap
Enterprise Value
Shares in issue (ADS)
12-month range
Free float40%
Company Code
Corporate clientYes

Company description

Hutchison China MediTech is a Hong Kong headquartered biopharma with an established Commercial Platform in China, and a diverse pipeline of first-in-class/best-in-class selective oral tyrosine kinase inhibitors (Innovation Platform). Its pipeline, discovered in-house, is in development for the China and global oncology markets.


Franc Gregori
+44 (0) 20 3637 5041

Mick Cooper PhD
+44 (0) 20 3637 5042

Lala Gregorek
+44 (0) 20 3637 5043

Exhibit 1: Summary of financials
Source: Company, Trinity Delta  Note: Adjusted numbers exclude exceptionals. Historic and forecast EPS are adjusted for one-to-ten ordinary share split, with new ADS ratio of 1:5 shares. Our estimate of $250m proceeds from the proposed equity raise are shown as short-term debt in FY20e, until transaction size, structure, and terms are confirmed.




Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publically available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2019 Trinity Delta Research Limited. All rights reserved.